CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Incannex Healthcare Inc.

IXHL
$42MMicro Cap

Next catalyst

Phase 2April 2027

IHL-42X: dronabinol + acetazolamide

Obstructive Sleep Apnea (OSA)

Get an email about IXHL's next catalysts

Track Incannex Healthcare (IXHL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 1 past

Phase 2Next

IHL-42X: dronabinol + acetazolamide Phase 2 Est. Readout (DReAMzz)

April 2027~IHL-42X: dronabinol + acetazolamide120

Estimated primary completion for IHL-42X: dronabinol + acetazolamide trial (NCT07635563) in Obstructive Sleep Apnea (OSA). Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈNorth AmericaNORWEST NSW12 employees
Drug Pipeline

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in Incannex Healthcare Inc.'s drug pipeline?β†’

CatalystAlert tracks 4 drug candidates in Incannex Healthcare Inc.'s (IXHL) pipeline across Phase 3, Phase 2. Its lead program is IHL-42X (Optimal Dose) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Incannex Healthcare Inc.'s next FDA catalyst?β†’

Incannex Healthcare Inc.'s (IXHL) next tracked catalyst is a Phase 2 readout expected April 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track IXHL biotech catalysts?β†’

Add IXHL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Incannex Healthcare Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply